Good News for ITP Patients: Ianalumab + Eltrombopag Prolongs Time to Treatment Failure VS Eltrombopag Alone
Roger Schutgens, Professor of Thrombosis and Haemostasis at UMC Utrecht, shared on LinkedIn:
“Good news for patients with ITP.
Recently, the results of the VAYHIT2 trial have been published in The New England Journal of Medicine, showing that a course of B-cell–targeted therapy (ianalumab) combined with eltrombopag significantly prolongs time to treatment failure compared to eltrombopag alone in adults with immune thrombocytopenia after first-line steroids (13 months versus 4.7 months).
More patients were able to taper and discontinue eltrombopag (62% versus 39%), supporting the concept of early, disease-modifying treatment in ITP.
It was a joyfull ride to be part of this endeavor.”
Title: Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Authors: Adam Cuker, Thomas Stauch, Nichola Cooper et al.
Read the full article.
Hemostasis Today has more posts you may find interesting.
-
Aug 22, 2026, 17:05Mostafa Elshazly: Managing Anticoagulant-Related Bleeding in Clinical Practice
-
Aug 22, 2026, 17:01Cesarovic Nikola: FDA Data Reanalysis Raises Questions About Moderna’s mFLUSIVA Risk-Benefit Profile
-
Aug 22, 2026, 16:38Andreas Linkermann: Decoding the Chain Reaction of Ferroptotic Cell Death
-
Aug 22, 2026, 16:33Nicolas Hulscher: FDA Data Reanalysis Raises Alarms Over Moderna’s MFLUSIVA
-
Aug 22, 2026, 16:19Moti Haim: Transforming AF Care in the Elderly
-
Aug 22, 2026, 16:12Hussam Hammoud: A Slap Is Not “Just a Slap” When the Patient Has Hemophilia
-
Aug 22, 2026, 15:53Howard Smith: Publix’s GreenWise Organic Frozen Berries Have E. coli Contamination
-
Aug 22, 2026, 15:13Arthur Allen: Empowering Clinicians to Act
-
Aug 22, 2026, 15:11Bassem M. Mohammed: Factor VIII Structure Analysis Makes the Cover of the Journal of Thrombosis and Haemostasis